Jubilant Pharmova Ltd - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to development of a novel oral formulation of Remdesivir with successful completion of safety and pharmacokinetic/absorption studies.<BR> <BR> We request you to take the same on record.<BR>